ZYDUSLIFE Stock Overview
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Zydus Lifesciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹937.00 |
| 52 Week High | ₹1,031.70 |
| 52 Week Low | ₹484.95 |
| Beta | 0.55 |
| 1 Month Change | -3.39% |
| 3 Month Change | 30.04% |
| 1 Year Change | 82.40% |
| 3 Year Change | 69.58% |
| 5 Year Change | 189.24% |
| Change since IPO | 10,699.19% |
Recent News & Updates
Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?
Mar 18
Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%
Feb 28Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report
Feb 12Recent updates
Does Zydus Lifesciences (NSE:ZYDUSLIFE) Deserve A Spot On Your Watchlist?
Mar 18Earnings Not Telling The Story For Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Shares Rise 28%
Feb 28Analyst Estimates: Here's What Brokers Think Of Zydus Lifesciences Limited (NSE:ZYDUSLIFE) After Its Third-Quarter Report
Feb 12Zydus Lifesciences (NSE:ZYDUSLIFE) Could Easily Take On More Debt
Dec 27Here's Why Zydus Lifesciences (NSE:ZYDUSLIFE) Has Caught The Eye Of Investors
Dec 06With EPS Growth And More, Zydus Lifesciences (NSE:ZYDUSLIFE) Makes An Interesting Case
Aug 23Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
Jul 17We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Jul 15Zydus Lifesciences' (NSE:ZYDUSLIFE) Upcoming Dividend Will Be Larger Than Last Year's
Jun 24Zydus Lifesciences (NSE:ZYDUSLIFE) Is Increasing Its Dividend To ₹6.00
Jun 10Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Increased To ₹6.00
May 21Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Feb 15We Think Zydus Lifesciences (NSE:ZYDUSLIFE) Can Stay On Top Of Its Debt
Nov 13Zydus Lifesciences Limited (NSE:ZYDUSLIFE) Shares Could Be 23% Below Their Intrinsic Value Estimate
Aug 09Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jul 25Zydus Lifesciences (NSE:ZYDUSLIFE) Has Announced That Its Dividend Will Be Reduced To ₹2.50
Jul 10Zydus Lifesciences (NSE:ZYDUSLIFE) Seems To Use Debt Quite Sensibly
Jul 07Zydus Lifesciences' (NSE:ZYDUSLIFE) Shareholders Will Receive A Smaller Dividend Than Last Year
Jun 23Zydus Lifesciences (NSE:ZYDUSLIFE) Is Reducing Its Dividend To ₹2.50
Jun 09Zydus Lifesciences' (NSE:ZYDUSLIFE) Dividend Will Be Reduced To ₹2.50
May 26If You Like EPS Growth Then Check Out Zydus Lifesciences (NSE:ZYDUSLIFE) Before It's Too Late
May 17Shareholder Returns
| ZYDUSLIFE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -5.8% | -2.2% | -2.1% |
| 1Y | 82.4% | 55.3% | 45.3% |
Return vs Industry: ZYDUSLIFE exceeded the Indian Pharmaceuticals industry which returned 55.3% over the past year.
Return vs Market: ZYDUSLIFE exceeded the Indian Market which returned 45.3% over the past year.
Price Volatility
| ZYDUSLIFE volatility | |
|---|---|
| ZYDUSLIFE Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: ZYDUSLIFE has not had significant price volatility in the past 3 months.
Volatility Over Time: ZYDUSLIFE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 23,026 | Sharvil Patel | www.zyduslife.com |
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, metabolic disorder, and liver diseases.
Zydus Lifesciences Limited Fundamentals Summary
| ZYDUSLIFE fundamental statistics | |
|---|---|
| Market cap | ₹950.74b |
| Earnings (TTM) | ₹29.56b |
| Revenue (TTM) | ₹190.24b |
31.9x
P/E Ratio5.0x
P/S RatioIs ZYDUSLIFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZYDUSLIFE income statement (TTM) | |
|---|---|
| Revenue | ₹190.24b |
| Cost of Revenue | ₹64.73b |
| Gross Profit | ₹125.51b |
| Other Expenses | ₹95.95b |
| Earnings | ₹29.56b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 30, 2024
| Earnings per share (EPS) | 29.38 |
| Gross Margin | 65.97% |
| Net Profit Margin | 15.54% |
| Debt/Equity Ratio | 0.9% |
How did ZYDUSLIFE perform over the long term?
See historical performance and comparison